Your Article Summary
See Latest ArticlesCost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected intensive care unit-acquired candidemia among patients with sepsis: a model simulation
Critical Care, 07/02/09
Zilberberg MD et al. - Recent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. Given the increasing likelihood of azole resistance among candidal isolates, empiric treatment of ICU-AC with 100 mg daily MIC is a cost effective alternative to FLU.
Related Articles
Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants
Clinical Pharmacology & Therapeutics, 11/06/09
Relevance Score: 87%
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
Critical Care, 10/20/09
Relevance Score: 84%
A Survival Case of ABO-Incompatible Liver Transplantation Complicated With Severe Preoperative Infection and Subsequent Overwhelming Postsplenectomy Infection
Transplantation Proceedings, 11/18/09
Relevance Score: 80%
Candidiasis: New agents for invasive infections
The Clinical Advisor, 10/06/09
Relevance Score: 77%
Today in Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Pneumonia Recovery; Discrepancies in Perspectives of the Radiologist, Physician and Patient
Journal of General Internal Medicine, 12/11/09
HIV Risk Reduction Among Detained Adolescents: A Randomized, Controlled Trial
Pediatrics, 12/11/09
Transmission of Pandemic H1N1 Influenza Virus and Impact of Prior Exposure to Seasonal Strains or Interferon Treatment
Journal of Virology, 12/11/09